Heart rate-lowering drug improves exercise capacity in patients with stable angina

Results from a late-breaking clinical trial, presented at the 2008 Canadian Cardiology Congress (CCC) in Toronto, show for the first time that combining the pure heart rate reduction medication ivabradine to current treatments of patients with stable angina improves their exercise capacity...

Read the whole article on

More from